New online first articles from JAMA Oncology (2024)

Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals

Kemi M.Doll,MD, MSCR; MindyPike,PhD; JuliannaAlson,MPH; et al.

has audio

JAMA Oncol. Published online June 27, 2024. doi:10.1001/jamaoncol.2024.1891

This diagnostic study of Black patients assesses the false-negative probability and accuracy of ultrasonography-measured endometrial thickness thresholds as triage for endometrial cancer diagnosis.

• Audio: Endometrial Thickness as Diagnostic Triage for Endometrial Cancer in Black Individuals

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy

Veerle C. M.Geurts,MD; SaraBalduzzi,PhD; Tessa G.Steenbruggen,MD, PhD; et al.

JAMA Oncol. Published online June 27, 2024. doi:10.1001/jamaoncol.2024.1917

This cohort study examines the association between the presence of stromal tumor-infiltrating lymphocytes and survival among patients with stage I triple-negative breast cancer (TNBC) for whom chemotherapy may not be beneficial.

Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial

Stephen G.Chun,MD; ChenHu,PhD; Ritsuko U.Komaki,MD; et al.

JAMA Oncol. Published online June 27, 2024. doi:10.1001/jamaoncol.2024.1841

This secondary analysis of a phase 3 randomized clinical trial compared survival and safety outcomes of intensity-modulated radiotherapy to 3-dimensional conformal radiotherapy in combined modality treatment of patients with unresectable locally advanced non–small cell lung cancer.

A Case of Gastric Thickening and a Large Ovarian Mass

BinbinZheng-Lin,MD, MSc; KatalinKelemen,MD, PhD; AllisonRosenthal,DO

has active quiz

JAMA Oncol. Published online June 27, 2024. doi:10.1001/jamaoncol.2024.1816

A 35-year-old female patient with hypothyroidism and Ehler-Danlos syndrome presents with fatigue, abdominal distension, and dyspnea. What is your diagnosis?

Assessing the Evidence for Circulating Tumor HPV DNA in Patients With Oropharyngeal Cancer

Nancy Y.Lee,MD; Luc G. T.Morris,MD, MSc; MaximilianDiehn,MD, PhD

JAMA Oncol. Published online June 27, 2024. doi:10.1001/jamaoncol.2024.1821

This Viewpoint evaluates the use of tumor tissue–modified human papillomavirus (HPV) DNA in identifying minimal residual disease.

Advancing Precision Equity With Multicancer Detection Liquid Biopsies

Nicholas P.sem*nkovich,MD, PhD; GautumAgarwal,MD; Aadel A.Chaudhuri,MD, PhD

JAMA Oncol. Published online June 27, 2024. doi:10.1001/jamaoncol.2024.1860

This Viewpoint discusses the clinical and socioeconomic potential of multicancer detection liquid biopsies.

Comprehensive Risk Stratification to Guide an Optimal Preventive Strategy for Breast Radiation Dermatitis

Henry C. Y.Wong,MBBS; SaverioCaini,MD, PhD; KimberlyCorbin,MD

JAMA Oncol. Published online June 27, 2024. doi:10.1001/jamaoncol.2024.2206

Comprehensive Risk Stratification to Guide an Optimal Preventive Strategy for Breast Radiation Dermatitis—Reply

Avidan UrielNeumann,PhD; Kai JoachimBorm,MD; ClaudiaTraidl-Hoffmann,MD

JAMA Oncol. Published online June 27, 2024. doi:10.1001/jamaoncol.2024.2209

Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial

MichaelCecchini,MD; Ronald R.Salem,MD; MarieRobert,MD; et al.

open access

JAMA Oncol. Published online June 20, 2024. doi:10.1001/jamaoncol.2024.1575

This nonrandomized controlled trial assesses whether neoadjuvant modified 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) leads to early control of micrometastasis and improves survival.

• Invited Commentary

  The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma—Progress or Passive Acceptance?

  PriyadarshiniPathak,MBBS; Colin D.Weekes,MD, PhD; Rachna T.Shroff,MD, MS

  JAMA Oncol

Performance of Tumor Surveillance for Children With Cancer Predisposition

AliseBlake,MS, CGC; Melissa R.Perrino,MD; Cara E.Morin,MD, PhD; et al.

JAMA Oncol. Published online June 20, 2024. doi:10.1001/jamaoncol.2024.1878

This cohort study evaluates surveillance outcomes across a wide spectrum of cancer predisposition syndromes in children and young adults.

Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial

WenzheFan,MD; BowenZhu,MSc; ShulingChen,MD; et al.

JAMA Oncol. Published online June 20, 2024. doi:10.1001/jamaoncol.2024.1831

This randomized clinical trial evaluates the efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib vs TACE alone for patients with recurrent intermediate-stage hepatocellular carcinoma.

Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review

TimothéeOlivier,MD; AlysonHaslam,PhD; VinayPrasad,MD, MPH

JAMA Oncol. Published online June 20, 2024. doi:10.1001/jamaoncol.2024.1569

This systematic review examines the proportion and quality of postrecurrence treatment among patients in US Food and Drug Administration (FDA) registration trials of anticancer therapy in the neoadjuvant or adjuvant setting.

Current Management of Desmoid Tumors: A Review

BerndKasper,MD, PhD; Elizabeth H.Baldini,MD; SylvieBonvalot,MD, PhD; et al.

has active quiz

JAMA Oncol. Published online June 20, 2024. doi:10.1001/jamaoncol.2024.1805

This review describes the process of updating the global evidence-based consensus guideline on management of desmoid tumor.

The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma—Progress or Passive Acceptance?

PriyadarshiniPathak,MBBS; Colin D.Weekes,MD, PhD; Rachna T.Shroff,MD, MS

JAMA Oncol. Published online June 20, 2024. doi:10.1001/jamaoncol.2024.0870

Piercing the Fog

AntonioYaghy,MD

JAMA Oncol. Published online June 20, 2024. doi:10.1001/jamaoncol.2024.1865

Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer: A Nonrandomized Clinical Trial

SongDong,PhD; ZhenWang,PhD; Jia-TaoZhang,PhD; et al.

open access

JAMA Oncol. Published online June 13, 2024. doi:10.1001/jamaoncol.2024.1779

This nonrandomized clinical trial assesses the feasibility of using a circulating tumor DNA−guided adaptive de-escalation tyrosine kinase inhibitor strategy in patients with advanced non−small cell lung cancer to achieve complete remission after local consolidative therapy.

Stereotactic Ablative Radiotherapy for Gynecological Oligometastatic and Oligoprogessive Tumors

Elysia K.Donovan,MD, MSc; Simon S.Lo,MBChB; SushilBeriwal,MD, MBA; et al.

JAMA Oncol. Published online June 13, 2024. doi:10.1001/jamaoncol.2024.1796

This cohort study evaluates the outcomes of stereotactic ablative radiotherapy in patients with oligometastatic and oligoprogressive gynecologic cancers.

Home Time Among Older Adults With Acute Myeloid Leukemia Following Chemotherapy

Daniel R.Richardson,MD, MA, MSc; XiZhou,PhD; KatherineReeder-Hayes,MBA, MD; et al.

JAMA Oncol. Published online June 13, 2024. doi:10.1001/jamaoncol.2024.1823

This retrospective cohort study quantifies and compares home time for older patients with newly diagnosed acute myeloid leukemia receiving either hypomethylating agents or anthracycline-based chemotherapy.

Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer

Christopher W.Wheldon,PhD

JAMA Oncol. Published online June 13, 2024. doi:10.1001/jamaoncol.2024.1586

This Viewpoint discusses the importance of concentrating research efforts and clinical training on sexual and gender minority individuals who survive cancer, particularly on sexual rehabilitation.

Valid Analysis of Brain-Specific Progression-Free Survival

StephanieArmbruster,MSc; Ethan B.Ludmir,MD; Lee-JenWei,PhD

JAMA Oncol. Published online June 13, 2024. doi:10.1001/jamaoncol.2024.1693

Valid Analysis of Brain-Specific Progression-Free Survival

YuandongYu,MD; FengjunCao,MD; GuoxingWan,MD

JAMA Oncol. Published online June 13, 2024. doi:10.1001/jamaoncol.2024.1696

Valid Analysis of Brain-Specific Progression-Free Survival—Reply

Tom Wei-WuChen,MD, PhD; Ming-ShenDai,MD, PhD; Yen-ShenLu,MD, PhD

JAMA Oncol. Published online June 13, 2024. doi:10.1001/jamaoncol.2024.1699

Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy

Victoria A.Sanchez,AuD, PhD; Paul C.DinhJr,PhD; Patrick O.Monahan,PhD; et al.

JAMA Oncol. Published online June 6, 2024. doi:10.1001/jamaoncol.2024.1233

This cohort study evaluates cisplatin-related hearing loss with comprehensive audiologic assessments, assesses the longitudinal progression of cisplatin-related hearing loss, and identifies factors associated with risk.

Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis

OmarEl-Taji,MBChB, MRes; SamihTaktak,MBBS; CraigJones,MBChB, MRes; et al.

JAMA Oncol. Published online June 6, 2024. doi:10.1001/jamaoncol.2024.1549

This systematic review and meta-analysis investigates the incidence of cardiovascular events with addition of novel androgen receptor signaling inhibitors (ARSI) to standard of care in locally advanced and metastatic prostate cancer.

• Invited Commentary

  Cardiovascular Risk in Prostate Cancer—A Call to Action?

  Katelyn M.Atkins,MD, PhD; Andriana P.Nikolova,MD, PhD

  JAMA Oncol

Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Clinical Trial

Ari J.Rosenberg,MD; NishantAgrawal,MD; AdityaJuloori,MD; et al.

JAMA Oncol. Published online June 6, 2024. doi:10.1001/jamaoncol.2024.1530

This phase 2 nonrandomized clinical trial evaluates effectiveness and tolerance of neoadjuvant nivolumab, nab-pacl*taxel, and carboplatin followed by response-adaptive therapy in patients with human papillomavirus−positive oropharyngeal cancer.

Lymphoma With a Skin Rash

AbhinavSinghal,MD; AparnaSharma,DM; Kalpa JyotiDas,MD

has active quiz

JAMA Oncol. Published online June 6, 2024. doi:10.1001/jamaoncol.2024.1558

A 62-year-old female had a generalized vesiculobullous rash on her face for 4 months. It started over the lips and gradually progressed to involve the oral mucosa and skin of the whole body. What is your diagnosis?

Radiation With Immunotherapy May Be a Double-Edged Sword—How Can We Learn From Recent Negative Clinical Trials?

Heather M.McGee,MD, PhD; Terence M.Williams,MD, PhD; PercyLee,MD

JAMA Oncol. Published online June 6, 2024. doi:10.1001/jamaoncol.2024.1527

This Viewpoint explains differences between recent studies using radiotherapy with immunotherapy and possible reasons for their different outcomes.

Cardiovascular Risk in Prostate Cancer—A Call to Action?

Katelyn M.Atkins,MD, PhD; Andriana P.Nikolova,MD, PhD

JAMA Oncol. Published online June 6, 2024. doi:10.1001/jamaoncol.2024.0860

Immunotherapy For US Patients With Metastatic Cancer at the End of Life

HirotakaHigashi,MD; AkihikoShimomura,MD, PhD; ChikakoShimizu,MD, PhD

JAMA Oncol. Published online June 6, 2024. doi:10.1001/jamaoncol.2024.1563

Immunotherapy For US Patients With Metastatic Cancer at the End of Life—Reply

DanKerekes,MD; SajidKhan,MD

JAMA Oncol. Published online June 6, 2024. doi:10.1001/jamaoncol.2024.1566

Assessing the Environmental and Downstream Human Health Impacts of Decentralizing Cancer Care

AndrewHantel,MD; ColinCernik,MS; Thomas P.Walsh,MPH; et al.

JAMA Oncol. Published online June 3, 2024. doi:10.1001/jamaoncol.2024.2744

This cohort study assesses potential reductions in greenhouse gas emissions and downstream health harms associated with telemedicine and fully decentralized cancer care.

Geographic Distribution of Clinical Trials for Advanced-Stage Cancer

Wade T.Swenson,MD, MPH, MBA; AbigailSwenson,BA; EmilyWestergard,DO; et al.

open access

JAMA Oncol. Published online June 3, 2024. doi:10.1001/jamaoncol.2024.1690

This quality improvement study evaluates the geographic distribution of clinical trials and assesses the distances patients with cancer must travel to access a clinical trial site.